Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…Abstract Number: 676 • 2013 ACR/ARHP Annual Meeting
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease
Background/Purpose: To investigate whether patients affected with any of the 3 subsets of early systemic sclerosis (SSc) i.e. Raynaud’s Phenomenon (RP) with SSc marker autoantibody…Abstract Number: 683 • 2013 ACR/ARHP Annual Meeting
HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials
Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems…Abstract Number: 686 • 2013 ACR/ARHP Annual Meeting
Blood Flow In The Hands Of a Predefined Homogeneous Systemic Sclerosis Population: The Presence Of Digital Ulcers and The Improvement With Bosentan
Background/Purpose: Digital ulcers (DU) are complications of systemic sclerosis (SSc) and arise as a result of ischaemia due to vasculopathy of the digital arteries (1).…Abstract Number: 652 • 2013 ACR/ARHP Annual Meeting
Pirfenidone and BIBF1120 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis
Background/Purpose: Pirfenidone (5-methyle-1-phenyl-2- [1H]-pyridone) and BIBF1120 (Nintedanib) are currently evaluated in clinical trials as a potential idiopathic pulmonary fibrosis (IPF). Pirfenidone was approved as the…Abstract Number: 2919 • 2013 ACR/ARHP Annual Meeting
The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Background/Purpose: In systemic sclerosis (SSc, scleroderma) vasculopathy can result in the end-stage manifestation of a digital ulcer (DU). We hypothesized that bedside flow mediated dilatation…Abstract Number: 2594 • 2013 ACR/ARHP Annual Meeting
Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment
Background/Purpose: Microangiopathy in systemic sclerosis is progressive over time [1, 2]. This study assesses microangiopathic evolution by nailfold videocapillarocopic (NVC) analysis after two treatment course…Abstract Number: 2599 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review
Background/Purpose: Mycophenolate reduces chronic allograft nephropathy and interstitial fibrosis by inhibiting TGF-β, which is an important molecule in the pathogenesis of systemic sclerosis (SSc). The…Abstract Number: 2600 • 2013 ACR/ARHP Annual Meeting
Shear Wave Elastography: A Novel Quantitative Approach For Evaluating Scleroderma Skin
Background/Purpose: Systemic sclerosis (SSc) is a multi-system disease with both visceral and cutaneous fibrosis. Dermal elasticity is reduced and stiffness increased due to excessive dermal…Abstract Number: 2601 • 2013 ACR/ARHP Annual Meeting
Modified Rodnan Ultrasound Skin Score: An Ultrasound Skin Scoring Approach In Systemic Sclerosis
Background/Purpose: Systemic sclerosis (SSc) is a multi-organ disease characterized by thickening, hardening and tightening of the skin. Skin thickening is described by physical exam…Abstract Number: 1714 • 2012 ACR/ARHP Annual Meeting
Gender Differences in Systemic Sclerosis: Relationship to Disease Specific Clinical Manifestations and Estradiol Levels
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by inflammation, autoantibody production, and increased production of extracellular matrix (ECM), resulting in fibrosis. We…Abstract Number: 1716 • 2012 ACR/ARHP Annual Meeting
Outcomes Linked to Intensive Treatment Trials in Systemic Sclerosis
Background/Purpose: A number of clinical trials using intensive immunosuppression followed by autologous haematopoietic stem cell transplantation (HSCT) in systemic sclerosis (SSc) are underway or have…Abstract Number: 1521 • 2012 ACR/ARHP Annual Meeting
A Possible Contribution of Decreased Cathepsin V Expression to the Development of Dermal Fibrosis, Proliferative Vasculopathy, and Altered Keratinocyte Phenotype in Systemic Sclerosis
Background/Purpose: Cathepsin V (CTSV) is a proteolytic enzyme potentially modulating angiogenic processes, collagen degradation, and keratinocyte differentiation. Although our latest paper demonstrated that cathepsin B,…Abstract Number: 1478 • 2012 ACR/ARHP Annual Meeting
Gender-Associated Differences in Disease Characteristics and Outcome in Systemic Sclerosis
Background/Purpose: Although significant female gender predominance is seen in majority of large systemic sclerosis (SSc) cohorts, multiple studies have suggested that male gender generally associates…Abstract Number: 1480 • 2012 ACR/ARHP Annual Meeting
The 15% Rule in Scleroderma: A Systematic Review of the Frequency of Organ Complications in Systemic Sclerosis
Background/Purpose : The prevalence of each organ complication in scleroderma (SSc) varies by definition used. However, it is important to be aware of several complications…